AI-Based DeepGEM Tool for Predicting Gene Mutations in NSCLC Patients: A Randomized Controlled Study

Inclusion Criteria: * Age between 18 and 75 years, inclusive, at the time of enrollment. * Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) with clinical stage II-IV as per the 8th edition of the AJCC staging system. * Availability of qualified histopathological whole-slide images that can be reviewed through the KindMED system(DeepGEM). * Successful mutation prediction of EGFR, ALK, or ROS1 by the DeepGEM AI tool. * No prior systemic anti-cancer therapy, including chemotherapy, targeted therapy, or immunotherapy. * Willing and able to comply with study requirements, including follow-up and treatment; written informed consent must be provided. Exclusion Criteria: * Prior systemic anti-tumor therapy (chemotherapy, radiotherapy, targeted therapy-including but not limited to monoclonal antibodies or tyrosine kinase inhibitors) before enrollment. * Failure of DeepGEM analysis or unqualified histopathological image quality. * History of any other malignancy within the past 5 years, except for adequately treated basal cell carcinoma of the skin or in situ carcinoma (e.g., cervical carcinoma in situ). * Cognitive or psychological barriers to understanding or accepting AI-based prediction or molecular testing. * Pregnant or breastfeeding women, or women of childbearing potential who are not using effective contraception. * Any other clinical condition that, in the opinion of the investigators, may interfere with the study protocol or compromise participant safety, including poor compliance with study procedures.